BRIEF published on 12/10/2024 at 10:51, 11 months 25 days ago Threshold crossing by Cyrille Tupin at ABIONYX PHARMA Voting Rights Actions Threshold Crossing ABIONYX Pharma Cyrille Tupin
BRIEF published on 11/14/2024 at 19:05, 1 year ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 1 year 1 month ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 1 month ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 1 month ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 1 month ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 3 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 3 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 5 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
Published on 12/05/2025 at 02:35, 4 hours 41 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 16 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 11 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 16 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 16 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 46 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 25 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 51 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 1 minute ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 16 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 31 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 32 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
